Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PLEC | Q15149 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910856 | 0.86 | L3MBTL1 (0.49) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL3210770 | 0.85 | PPARD (0.49) | L3MBTL1MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL9264758 | 0.82 | MAPT (0.49) | L3MBTL1MAPTNPSR1ATMMEN1 | |
| SCHEMBL3204291 | 0.82 | L3MBTL1 (0.51) | L3MBTL1MAPTNPSR1ALDH1A1GLA | |
| SCHEMBL15711441 | 0.82 | L3MBTL1 (0.51) | L3MBTL1MAPTNPSR1ALDH1A1GLA | |
| SCHEMBL910695 | 0.81 | L3MBTL1 (0.59) | L3MBTL1MAPTNPSR1ALDH1A1GLA | |
| SCHEMBL834561 | 0.81 | TAAR1 (0.58) | L3MBTL1MAPTALDH1A1GAA | |
| SCHEMBL3025748 | 0.79 | L3MBTL1 (0.61) | L3MBTL1MAPTNPSR1ALDH1A1GLA | |
| SCHEMBL4262567 | 0.79 | L3MBTL1 (0.60) | L3MBTL1MAPTNPSR1ALDH1A1GLA | |
| SCHEMBL31054 | 0.78 | L3MBTL1 (0.84) | L3MBTL1MAPTNPSR1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | disclosed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | L3MBTL1 874/4885MAPT 2499/4885NPSR1 2216/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | L3MBTL1 1100/4885MAPT 2324/4885NPSR1 4560/4885 |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | L3MBTL1 3695/4885MAPT 3999/4885NPSR1 2497/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | L3MBTL1 999/4885MAPT 2212/4885NPSR1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.